Treatment strategies for polycythemia vera: Observations in a Dutch “real‐world” cohort study

Ree-Pellikaan, Claire van de; Kreuk, Arne de; Schaar, C. G.; Beeker, Aart; Dompeling, Ellen C; Gerrits, C. J. H.; Houten, Anja A. van; Schipperus, Martin R.; Strobbe, Leonie; Posthuma, Eduardus F M; Klauke, K.; Westerweel, Peter E.

doi:10.1111/ejh.13291

Cited by 4 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cytoreductive therapy has been established in high‐risk ET, but the indication for use of cytoreduction in high‐risk PV with normal platelet and leukocyte counts has obviously not been adapted to all hematology centers in Sweden. Similar treatment practices have been described in Canada and the Netherlands …”

Section: Discussionmentioning

confidence: 99%

“…Similar treatment practices have been described in Canada 22 and the Netherlands. 26 Since the ECLAP study was published in 2004, 10 the benefit of low-dose aspirin in PV in preventing thromboembolic complications has been established. Despite of this knowledge and recommendations given by the Nordic MPN guidelines for many years, 14% of PV cases were not treated with anti-thrombotic therapy.…”

Section: Ta B L E 4 Characteristics Of Pv Patients At the Time Of Diamentioning

confidence: 99%

See 1 more Smart Citation

Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow‐up

Ahlstrand

Samuelsson

Lindgren

et al. 2020

European J of Haematology

View full text Add to dashboard Cite

Objective To explore the relative importance of risk factors, treatments, and blood counts for the occurrence of vascular complications and their impact on life expectancy in essential thrombocythemia (ET) and polycythemia vera (PV). Methods Nested case‐control study within the Swedish MPN registry. From a cohort of 922 ET patients and 763 PV patients, 71 ET and 81 PV cases with vascular complications were compared with matched controls. Results Incidence of vascular complications was 2.0 and 3.4 events per 100 patient‐years in ET and PV, respectively. At diagnosis, no significant risk factor differences were observed between cases and controls in neither of the diseases. At the time of vascular event, ET complication cases did not differ significantly from controls but in PV, cases had significantly higher WBCs and were to a lesser extent treated with anti‐thrombotic and cytoreductive therapy. Life expectancy was significantly decreased in both ET and PV cases compared with controls. Conclusions The risk of vascular complications is high in both ET and PV, and these complications have a considerable impact on life expectancy. The protective effect of anti‐thrombotic and cytoreductive therapy for vascular complications in PV underscores the importance of avoiding undertreatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Ta B L E 4 Characteristics Of Pv Patients At the Time Of Diamentioning

confidence: 99%

Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow‐up

Ahlstrand

Samuelsson

Lindgren

et al. 2020

European J of Haematology

View full text Add to dashboard Cite

show abstract

Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety

Masarova,

Mascarenhas,

Rampal

et al. 2024

Cancer

View full text Add to dashboard Cite

The oral Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib was approved by the US Food and Drug Administration in 2014 for treatment of patients with polycythemia vera (PV) who have an inadequate response to or intolerance of hydroxyurea (HU). PV is a chronic myeloproliferative neoplasm defined by primary absolute erythrocytosis, bone marrow hypercellularity, and JAK mutations such as JAK2V617F. Patients with PV experience burdensome symptoms and are at risk of thromboembolic events, in particular those with resistance to or intolerance of initial treatments such as HU. Other risks for patients with PV include progression of disease to more aggressive forms with worse prognoses, such as myelofibrosis or blast‐phase myeloproliferative neoplasms. This review summarizes the efficacy and safety of ruxolitinib from key phase 2 and 3 trials (MAJIC‐PV, RESPONSE, RESPONSE‐2, RELIEF, and Ruxo‐BEAT), large real‐world studies, and a decade of postmarketing surveillance safety data. The authors focus on improved blood count control, rates of thromboembolic events, symptom improvement, and markers of disease modification such as reduction of JAK2V617F allele burden in patients treated with ruxolitinib. They also discuss the well‐characterized safety profile of ruxolitinib regarding hematologic and other adverse events of interest. In the 10 years since its approval, ruxolitinib remains a safe and effective standard‐of‐care treatment for PV. As the treatment landscape for PV continues to evolve in the coming years, the efficacy and safety profiles of ruxolitinib suggest it will remain a preferred treatment as monotherapy and as a potential backbone of future combination regimens.

show abstract

Perioperative Management of Polycythemia

Zhao

Huang

Matson

et al. 2021

Essentials of Blood Product Management in Anesthesia Practice

View full text Add to dashboard Cite

Treatment strategies for polycythemia vera: Observations in a Dutch “real‐world” cohort study

Cited by 4 publications

References 24 publications

Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow‐up

Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow‐up

Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety

Perioperative Management of Polycythemia

Contact Info

Product

Resources

About